RxDoctor Payments Data

Michael Koehler, MD

Cardiovascular Disease · Oklahoma City, OKNPI 1902031487

Payments from drug & device makers

$2,519in general payments, 2019–2025

Across 164 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$524
  • AstraZeneca$467
  • Pfizer$396
  • Amgen$383
  • Boehringer Ingelheim$317
  • E.r. Squibb & Sons, L.L.C.$207
  • plus $226 from 8 others

What the payments were for

  • Food & beverage$2,49799%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,519 in reported general payments places this provider in the 40th percentile of 164 cardiovascular disease providers in Oklahoma.

See all cardiovascular disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$226,917
Medicare patients
2,206
Services billed
3,786

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban720$711,459
XareltoRivaroxaban125$144,149
EntrestoSacubitril/Valsartan114$106,653
FarxigaDapagliflozin Propanediol92$91,567
JardianceEmpagliflozin74$75,146
Repatha SureclickEvolocumab73$49,354
Repatha SyringeEvolocumab36$36,234
Ranolazine ErRanolazine122$13,053
Atorvastatin Calcium843$11,757
BrilintaTicagrelor14$9,969
Metoprolol Succinate617$8,180
Praluent PenAlirocumab13$7,694
Clonidine58$4,857
Ezetimibe183$4,700
Losartan Potassium322$4,336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$396$711,459720 claims
Johnson & JohnsonXarelto$30$144,149125 claims
NovartisEntresto$524$106,653114 claims
AstraZenecaFarxiga, Brilinta$467$101,536106 claims
Boehringer IngelheimJardiance$317$75,14674 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 164 cardiovascular disease providers in Oklahoma.

Other cardiovascular disease in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →